Stock MSB MESOBLAST LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mesoblast Limited

Equities

MSB

AU000000MSB8

Market Closed - Australian S.E.
Other stock markets
 02:10:23 2024-05-23 am EDT 		5-day change 1st Jan Change
1.18 AUD +2.61% Intraday chart for Mesoblast Limited +12.38% +280.65%
Apr. 01 ADRs End Higher; Connect Biopharma Climbs 26% DJ
Mar. 28 ADRs End Lower; NuCana Slides 15% DJ

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
MESOBLAST LIMITED Stock Mesoblast Limited
+280.65% 871M
C
MODERNA, INC. Stock Moderna, Inc.
+63.74% 62.59B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.81% 41.18B
B
LONZA GROUP AG Stock Lonza Group AG
+44.76% 40.29B
A
CELLTRION, INC. Stock Celltrion, Inc.
-8.93% 27.9B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.56% 26.21B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.98% 19.09B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.24% 13.08B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.57% 12.26B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.24% 12.05B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MSB Stock
  4. Ratings Mesoblast Limited